tiprankstipranks
Advertisement
Advertisement
Cathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today
PremiumThe FlyCathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today
24d ago
CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF
Premium
Market News
CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF
25d ago
Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million
Premium
Company Announcements
Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million
25d ago
Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
PremiumThe FlyMidday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
26d ago
Crispr Therapeutics announces proposed convertible senior notes offering
Premium
The Fly
Crispr Therapeutics announces proposed convertible senior notes offering
26d ago
Crispr Therapeutics AG Surges on Takeover Buzz and Hype
Premium
Weekend Updates
Crispr Therapeutics AG Surges on Takeover Buzz and Hype
1M ago
Crispr Therapeutics price target lowered to $67 from $69 at JPMorgan
PremiumThe FlyCrispr Therapeutics price target lowered to $67 from $69 at JPMorgan
2M ago
Crispr Therapeutics price target raised to $80 from $77 at Citi
Premium
The Fly
Crispr Therapeutics price target raised to $80 from $77 at Citi
2M ago
CRISPR Therapeutics: Casgevy Outperformance and 2026 Pipeline Catalysts Drive Raised $80 Target and Buy, High Risk Rating
Premium
Ratings
CRISPR Therapeutics: Casgevy Outperformance and 2026 Pipeline Catalysts Drive Raised $80 Target and Buy, High Risk Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100